A Phase 2 interventional study of pemetrexed and irinotecan in Metastatic Colorectal Cancer, sponsored by Eli Lilly and Company. Completed at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-05.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing pemetrexed in Colorectal Neoplasms — none open to participants now, none under way, none of them phase 3. Pemetrexed · Colorectal Neoplasms.
Among the 10 studies testing pemetrexed in Colorectal Neoplasms, this one is one of 2 that started in 2004, is one of 8 in phase 2, and was the 4th registered.
6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.
Browse Colorectal Neoplasms studies →None of the 10 studies testing pemetrexed in Colorectal Neoplasms is open now. The open studies under Colorectal Neoplasms, anywhere →
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9
First in 2004; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 76 across 4,810 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 37 across the 8 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 7 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
37 studies in Colorectal Neoplasms by Eli Lilly and Company: 4 open now, 7 under way, none of them phase 3. Of 29 finished, 15 (52%) have results posted.
Among the 37 studies in Colorectal Neoplasms by Eli Lilly and Company, this one is the 25th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2004, is one of 16 in phase 2, and was the 9th registered.
Eli Lilly and Company’s Colorectal Neoplasms studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing pemetrexed in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 37 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
A non-randomized phase II study to determine the efficacy and safety of the combination of Pemetrexed and Irinotecan every two weeks in metastatic colorectal cancer patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pemetrexed · Drug: irinotecan
400 mg/m\^2, intravenous (IV), every 14 days x 12 cycles
Also known as: LY231514, Alimta
180 mg/m\^2, intravenous (IV), every 14 days x 12 cycles
Best Overall Tumor Response
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) = small changes that do not meet above criteria.
Time frame: baseline to measured progressive disease (up to 2 years follow-up)
Duration of Response
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Response was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions.
Time frame: time of response to progressive disease or death (up to 2 years follow-up)
Progression-Free Survival (PFS)
Defined as the time from study enrollment to the first date of disease progression or death as a result of any cause. PFS was censored at the date of the last follow-up visit for participants who were still alive and who had not progressed.
Time frame: baseline to measured progressive disease or death (up to 2 years follow-up)
Time to Treatment Failure
Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.
Time frame: baseline to stopping treatment (up to 2 years follow-up)
Overall Survival
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
Time frame: baseline to date of death from any cause (up to 2 years follow-up)
| Milestone | Pemetrexed + Irinotecan |
|---|---|
| Started | 46 |
| Completed | 7 |
| Not completed | 39 |
| Withdrew: Disease progression | 21 |
| Withdrew: Adverse event | 4 |
| Withdrew: Death | 2 |
| Withdrew: Entry criteria exclusion | 1 |
| Withdrew: Withdrawal by subject | 7 |
| Withdrew: Physician decision | 4 |
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) = small changes that do not meet above criteria.
| participants | Pemetrexed + Irinotecan |
|---|---|
| Partial Response | 6 |
| Stable Disease | 18 |
| Progressive Disease | 15 |
| Unknown | 5 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Response was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions.
| days | Pemetrexed + Irinotecan |
|---|---|
| Duration of Response | 236 (105 to 353) |
Defined as the time from study enrollment to the first date of disease progression or death as a result of any cause. PFS was censored at the date of the last follow-up visit for participants who were still alive and who had not progressed.
| days | Pemetrexed + Irinotecan |
|---|---|
| Progression-Free Survival (PFS) | 123 (60 to 146) |
Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.
| days | Pemetrexed + Irinotecan |
|---|---|
| Time to Treatment Failure | 66 (55 to 105) |
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
| days | Pemetrexed + Irinotecan |
|---|---|
| Overall Survival | 422 (305 to 602) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed + Irinotecan | — | — | — |
| Event | Pemetrexed + Irinotecan |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 3/44 |
| DiarrhoeaGastrointestinal disorders | 3/44 |
| VomitingGastrointestinal disorders | 2/44 |
| DehydrationMetabolism and nutrition disorders | 2/44 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/44 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/44 |
| MelaenaGastrointestinal disorders | 1/44 |
| NauseaGastrointestinal disorders | 1/44 |
| AstheniaGeneral disorders | 1/44 |
| General physical health deteriorationGeneral disorders | 1/44 |
| Event | Pemetrexed + Irinotecan |
|---|---|
| AstheniaGeneral disorders | 24/44 |
| NauseaGastrointestinal disorders | 18/44 |
| DiarrhoeaGastrointestinal disorders | 15/44 |
| VomitingGastrointestinal disorders | 11/44 |
| AnaemiaBlood and lymphatic system disorders | 10/44 |
| Weight decreasedInvestigations | 9/44 |
| ConstipationGastrointestinal disorders | 8/44 |
| AnorexiaMetabolism and nutrition disorders | 8/44 |
| NeutropeniaBlood and lymphatic system disorders | 7/44 |
| Abdominal painGastrointestinal disorders | 6/44 |
| Age Continuous(years) | Pemetrexed + Irinotecan |
|---|---|
| Mean | 60.8 ± 11.5 |
| Sex: Female, Male(Participants) | Pemetrexed + Irinotecan |
|---|---|
| Female | 13 |
| Male | 31 |
| Region of Enrollment(participants) | Pemetrexed + Irinotecan |
|---|---|
| France | 44 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(units on a scale) | Pemetrexed + Irinotecan |
|---|---|
| 0 - Fully Active | 24 |
| 1 - Ambulatory, Restricted Strenuous Activity | 15 |
| 2 - Ambulatory, No Work Activities | 5 |
| Pathological Diagnosis(participants) | Pemetrexed + Irinotecan |
|---|---|
| Adenocarcinoma of Colon | 22 |
| Adenocarcinoma of Rectum | 20 |
| Colorectal Cancer | 2 |
| Height(centimeters) | Pemetrexed + Irinotecan |
|---|---|
| Mean | 169.3 ± 8.5 |
| Weight(kilograms) | Pemetrexed + Irinotecan |
|---|---|
| Mean | 69.3 ± 11.7 |
The record gives a start of Jun 2004, a primary completion of Feb 2007 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Irinotecan